The company
Moderna, Inc.
MRNA · Nasdaq
Health CareBiotechnologyLeading
MRNA stood above a rising 150-day average in 44 of the last 52 weekly readings, including each of the last 44 weeks. It is 147.3% above that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).
Statistics
- Rotation
- Leading
- Weeks in an uptrend
- 44 in a row
- Industry in uptrend
- 15% -17 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $145.6M
- Officials’ trades on record
- 29
- Institutions holding
- 733 (+57)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 44 of 52 weeks.
17 Apr – 16 Oct
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
1 Nov 2024 – 1 Oct 2026
Open-market buys above the line and sales below, in dollars.
Congress and officials
29 disclosed lines: House 26, Senate 0, executive 3; 8 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| Maria Elvira Salazar House: U.S. House ClerkFL27 | sold | $1k–$15k | 24 Sep 2026filed 7 Oct 2026 |
| Maria Elvira Salazar House: U.S. House ClerkFL27 | sold | $1k–$15k | 19 Aug 2026filed 9 Sep 2026 |
| Maria Elvira Salazar House: U.S. House ClerkFL27 | bought | $1k–$15k | 19 Aug 2026filed 9 Sep 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $1k–$15k | 18 May 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $1k–$15k | 17 Mar 2026filed 14 May 2026 |
| Robert P. Bresnahan, Jr. House: U.S. House ClerkPA08 | sold | $1k–$15k | 8 Apr 2025filed 8 May 2025 |
| Robert P. Bresnahan, Jr. House: U.S. House ClerkPA08 | bought | $1k–$15k | 25 Feb 2025filed 27 Mar 2025 |
| Julie Johnson House: U.S. House ClerkTX32 | soldjoint | $1k–$15k | 15 Jan 2025filed 12 Feb 2025 |
| Josh Gottheimer House: U.S. House ClerkNJ05 | soldjoint | $1k–$15k | 1 Feb 2024filed 7 Mar 2024 |
| Josh Gottheimer House: U.S. House ClerkNJ05 | soldjoint | $1k–$15k | 15 Sep 2023filed 15 Oct 2023 |
| Daniel S. Goldman House: U.S. House ClerkNY10 | sold | $50k–$100k | 12 Jul 2023filed 13 Aug 2023 |
| Daniel S. Goldman House: U.S. House ClerkNY10 | bought | $50k–$100k | 10 Apr 2023filed 19 May 2023 |
Insiders
Buy orders, 12 months0
Sale orders, 12 months17
Buyers · sellers0 · 6
| Who | Did | Shares | Traded |
|---|---|---|---|
| Stephen HogePresident | sold | 39,145at $220.72 | 15 Oct 2026filed 16 Oct 2026 |
| Stephen HogePresident | sold | 38,774at $213.47 | 14 Oct 2026filed 16 Oct 2026 |
| Stephen HogePresident | sold | 450at $214.15 | 14 Oct 2026filed 16 Oct 2026 |
| Stephen HogePresident | sold | 40,281at $146.07 | 15 Sep 2026filed 16 Sep 2026 |
| Stephen HogePresident | sold | 40,294at $144.13 | 14 Sep 2026filed 16 Sep 2026 |
| James M. MockChief Financial Officer | sold | 19,836at $134.49 | 10 Sep 2026filed 14 Sep 2026 |
| James M. MockChief Financial Officer | sold | 15,000at $134.49 | 10 Sep 2026filed 14 Sep 2026 |
| Shannon Thyme KlingerChief Legal Officer | sold | 3,471at $139.95 | 1 Sep 2026filed 3 Sep 2026 |
| Stephane BancelChief Executive Officer | sold | 147,473at $56.21 | 5 Aug 2026filed 7 Aug 2026 |
| Stephane BancelChief Executive Officer | sold | 124,838at $56.96 | 5 Aug 2026filed 7 Aug 2026 |
| Stephane BancelChief Executive Officer | sold | 39,891at $58.12 | 5 Aug 2026filed 7 Aug 2026 |
| Stephane BancelChief Executive Officer | sold | 187,044at $58.79 | 5 Aug 2026filed 7 Aug 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Holders733+57 on the quarter
New · exited146 · 89
Reported value$22.1B
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| FMR LLCadded · filed 13 Aug 2026 | 51,859,891$3.6B | +6,187,867+13.5% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 30,599,409$2.1B | +963,533+3.3% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 23,208,792$1.6B | +336,334+1.5% |
| Capital World Investorsadded · filed 12 Aug 2026 | 22,276,996$1.6B | +3,579,302+19.1% |
| BAILLIE GIFFORD & COreduced · filed 6 Aug 2026 | 18,206,778$1.3B | -1,779,098−8.9% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 15,726,193$1.1B | +864,784+5.8% |
| VANGUARD PORTFOLIO MANAGEMENT LLCreduced · filed 13 Aug 2026 | 15,581,313$1.1B | -35,054−0.2% |
| GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026 | 9,710,335$678.8M | +275,203+2.9% |
| MORGAN STANLEYadded · filed 13 Aug 2026 | 9,538,094$668.0M | +1,066,831+12.6% |
| Theleme Partners LLPadded · filed 13 Aug 2026 | 8,057,571$564.3M | +9,326+0.1% |
31 Mar 2023 – 30 Jun 2026
News
Moderna (MRNA) Was Removed From the Nasdaq-100 and Is Going Back In. What Changed?insidermonkey.com · 9 Oct 2026Moderna (MRNA) Soars 175% in Q3: Can The Stock Keep Running?insidermonkey.com · 5 Oct 2026Jim Cramer Says This Stock Could Rise Like Moderna (MRNA)insidermonkey.com · 5 Oct 2026Moderna, Inc. to Join the Nasdaq-100 Index® Beginning October 9, 2026manilatimes.net · 2 Oct 2026Moderna Stock Falls 7% After Adding Chief Operating Officer Rolerttnews.com · 30 Sep 2026Moderna Names Juan Andres As Chief Operating Officerrttnews.com · 30 Sep 2026Moderna Adds Chief Operating Officer Role as Company Expands into Oncology ...pr-inside.com · 30 Sep 2026Moderna, Inc.: Moderna Adds Chief Operating Officer Role as Company Expands into Oncologyfinanznachrichten.de · 30 Sep 2026
Everyone who traded it
Same industry
Government contracts
Awards3
Total$10.0B
Latest11 Aug 2020
100M SARS-COV-2 MRNA-1273 VACCINE DOSESDepartment of Defense · $8.2B · 11 Aug 2020DEVELOPMENT OF MRNA VACCINE TO LICENSURE FOR THE PREVENTION OF COVID-19. CLIN 0001 - PRE-AWARD COST, CLIN 0002 - DEVELOPMENT OF MRNA VACCINE TO BLA AND CLIN 0003 - DOMESTIC MANUFACTURING SCALE-OUTDepartment of Health and Human Services · $1.8B · 3 Apr 2020MODERNA THERAPEUTICS, INC:ADVANCE THE DEVELOPMENT OF AN MRNA VACCINE FOR THE PREVENTION OF ZIKA VIRUS:: IGF::OT::IGFDepartment of Health and Human Services · $73.0M · 1 Sep 2016
From its SEC filings
Analyst forecasts
No analyst forecasts yet.